Subscribe to Newsletter
Diagnostics Neurology, Biochemistry and molecular biology

Targeting Postpartum Depression

Postpartum depression (PPD) is the most common complication of childbirth. It affects around 13 percent of mothers and is associated with over a ten-fold increase in suicide risk compared with healthy individuals. Researchers from Canada and Germany now hope they can develop new treatment strategies through their discovery of a new biomarker (1).

Lead author of the study, Julia Sacher from the Max-Planck Institute for human cognitive and brain sciences in Leipzig, Germany, says PPD is an immense public health issue. “It is often not diagnosed and in many cases not adequately treated. A mother’s mental health and well-being have profound effects on her child’s physical and emotional development and impact the entire family,” she explained.

Sacher believes that the discovery of the biomarker – elevated monoamine oxidase A (MAO-A) in the brain – could open up new directions to improve diagnosis, treatment and effective prevention strategies.

The researchers used positron emission tomography (PET), to measure MAO-A density in the prefrontal and anterior cingulate cortex in the brain. They found that in women experiencing PPD, MAO-A values were 21 percent higher than in healthy controls.

“Our data argue for clinical trials of MAO-A inhibitors for PPD, and the development of new, well tolerated MAO-A inhibitors that either rapidly wash out of the periphery or which have high brain to periphery concentrations,” says Sacher.

According to the study, the biomarker doesn’t just identify depression; substantial MAO-A binding changes were also observed in the subclinical group; women who did not meet the criteria for full PPD, but who reported increased crying and sadness. This group also showed elevated MAO-A levels in brain regions important for balancing emotions and mood, such as the prefrontal cortex and the anterior cingulate cortex. For the researchers, this was an interesting find. “Either these women will go on to develop PPD at some later time or they have some sort of compensation mechanism protecting them from developing the full-blown clinical disorder,” says Sacher. “Based on our neurobiological model for PPD, promoting normalization of MAO-A levels after the immediate postpartum period might reduce the probability of developing the full clinical disorder.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. J. Sacher et al., “Relationship of Monoamine Oxidase-A Distribution Volume to Portpartum Depression and Postpartum Crying”, Neuropsychopharmacology (2014). doi:10.1038/npp.2014.190 [Epub ahead of print].
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine